SCHEMBL1593317

SCHEMBL1593317

CN1CCCN(Cc2nc3ccccc3c(=O)n2-c2c(F)cc(F)cc2Cl)CC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
HSD17B10 Q99714 1/20 0.54
HIF1A Q16665 8/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
STAT1 P42224 2/20 0.47
HTT P42858 1/20 0.47
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
MAPK1 P28482 1/20 0.42
STAT3 P40763 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SLC7A11 Q9UPY5 2/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15368092 0.92 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AHSD17B10HIF1A
SCHEMBL1592850 0.85 ALDH1A1 (0.54) ALDH1A1MEN1KMT2AHSD17B10HIF1A
SCHEMBL15368089 0.78 HIF1A (0.55) ALDH1A1MEN1KMT2AHSD17B10HIF1A
SCHEMBL15368091 0.78 HIF1A (0.60) ALDH1A1MEN1KMT2AHSD17B10HIF1A
SCHEMBL1592822 0.77 HIF1A (0.56) ALDH1A1MEN1KMT2AHSD17B10HIF1A
SCHEMBL1592811 0.76 HIF1A (0.44) ALDH1A1MEN1KMT2AHSD17B10HIF1A
SCHEMBL1592785 0.75 HIF1A (0.48) ALDH1A1MEN1KMT2AHSD17B10HIF1A
SCHEMBL12610280 0.73 HIF1A (0.56) ALDH1A1MEN1KMT2AHSD17B10HIF1A
SCHEMBL1593598 0.73 HIF1A (0.92) ALDH1A1MEN1KMT2AHSD17B10HIF1A
SCHEMBL14464267 0.72 PDE7A (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575143-B2 3-aryl-substituted quinazolones, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8575143-B2 3-aryl-substituted quinazolones, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-8575143-B2 3-aryl-substituted quinazolones, and uses thereof PROLEXYS PHARMACEUTICALS, INC. (US) 2013-11-05 US disclosed
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof Prolexys Pharmaceuticals ,Inc. (US) 2011-04-21 US disclosed
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof Prolexys Pharmaceuticals ,Inc. (US) 2011-04-21 US disclosed
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof Prolexys Pharmaceuticals ,Inc. (US) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092489-A1 3-Aryl-Substituted Quinazolones, and Uses Thereof MKI67, MCL1, HCCS ALDH1A1 365/4885MEN1 2337/4885KMT2A 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.